Vistagen Therapeutics, Inc. (VTGN)

Vistagen Therapeutics' stock price has experienced a significant decline over the past six months and year. From January 10, 2025, to January 8, 2026, the share price declined by 76.30%. Key events impacting the stock include the announcement of disappointing topline results from the PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol in December 2025, the appointment of Nick Tressler as Chief Financial Officer in December 2025, the report of fiscal year 2026 second-quarter financial results and corporate update in November 2025, a 54% jump in Q1 R&D expense in August 2025, the reaffirmation of the timeline for PALISADE-3 and PALISADE-4 trials in February 2025, and the execution of a 1-for-30 reverse stock split in June 2023.

As a clinical-stage biopharmaceutical company, Vistagen Therapeutics, Inc. is primarily focused on the research, development, and commercialization of new medications. Therefore, the concept of "demand seasonality" is not directly applicable at this stage, as the company's revenue is not driven by the seasonal sales of commercialized products.

Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company focused on developing and commercializing new medications for neuropsychiatric and neurological disorders, operating within the Biotechnology industry. The company's product portfolio consists of intranasal product candidates known as "pherines," which leverage nose-to-brain neurocircuitry. Key product candidates include Fasedienol (PH94B) for anxiety disorders, Itruvone (PH10) for major depressive disorder, AV-101 for depression and neurological disorders, PH15 for cognition improvement, PH80 for vasomotor symptoms due to menopause, and PH284 for Wasting syndrome (Cachexia).

Vistagen Therapeutics, Inc. is headquartered in South San Francisco, California, United States. The company has a collaboration agreement with AffaMed Therapeutics, Inc. for fasedienol.

Vistagen Therapeutics has received a consensus rating of "Reduce" from Wall Street analysts, with an average price target of $0.95. While some investing groups have expressed positive sentiment, the disappointing topline results from the PALISADE-3 Phase 3 study in December 2025 likely negatively impacted its reputation and investor confidence.

Vistagen Therapeutics, Inc. has notable institutional ownership, with 77 to 88 institutional owners and shareholders holding approximately 23,874,565 shares, accounting for about 59.16% to 61.11% of the company. Major institutional owners include Janus Henderson Group Plc, Orbimed Advisors Llc, TCG Crossover Management, LLC, StemPoint Capital LP, Nantahala Capital Management, LLC, Vanguard Group Inc, Commodore Capital Lp, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Ikarian Capital, LLC, Soleus Capital Management, L.P., Blackrock, Inc., Geode Capital Management LLC, and JPMorgan Chase & Co.